The Promise of B-Cell Epitope Immunotherapies - Combinatorial HER-2, PD-1, PD-L1 and CTLA-4 Checkpoint Inhibitor Peptide Vaccines

Explore the cutting-edge field of B-cell epitope immunotherapies in this 49-minute webinar presented by Dr. Pravin T.P. Kaumaya, an internationally recognized expert in peptide vaccine research and cancer immunotherapy. Discover how specially designed chimeric B-cell epitope peptides can serve as an alternative to expensive monoclonal antibodies by eliciting natural polyclonal antibody responses for cancer treatment. Learn about the development of combinatorial approaches targeting HER-2, PD-1, PD-L1, and CTLA-4 checkpoint inhibitors through innovative peptide vaccines that incorporate promiscuous T-cell epitopes. Understand the advantages of active immunotherapy over passive approaches, including improved safety profiles, cost-effectiveness, and reduced resistance compared to traditional humanized monoclonal antibodies like Trastuzumab and Pertuzumab. Examine the underappreciated role of B-cell humoral immunity in cancer and how this paradigm shift in immune-oncology could revolutionize combination immunotherapy strategies. Gain insights into translational research approaches that bridge bench-to-clinic development of next-generation cancer vaccines, including recent advances in PD-1-Vaxx B-cell peptide vaccines and combination platforms targeting multiple immune checkpoints such as TIGIT, TIM3, and LAG-3 for enhanced therapeutic efficacy in cancer treatment and prevention.